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SUMMARY 
 
Modeling and simulation in pharmacokinetics has has turned into the focus of pharmaceutical 
companies, driven by the emerging consensus that in silico predictions combined with in vitro 
data have the potential of significantly increasing  insight into pharmacokinetic processes. To 
adequately support in silico methodology, software tools need to be user-friendly and, at the 
same time, flexible. In brief, the software has to allow the realization of modeling ideas that 
are beyond current knowledge – in the form of a virtual lab. We present and discuss the 
necessary design principles and concepts. These have been implemented in the software 
package MEDICI-PK to demonstrate its feasibility and advantages. 
 
 
 
PHARMACOKINETICS IN DRUG DISCOVERY 
 
The medical benefits of a drug depend not only on its biological effect at  the target protein, 
but also on its “life cycle” within the organism - from its absorption into the blood, 
distribution to tissue and its eventual breakdown or excretion by the liver and kidneys. 
Pharmacokinetics is the study of the drug-organism interaction, in particular the investigation 
of absorption, distribution, metabolism, and excretion (ADME) processes [1,2]. Studying 
ADME profiles is widely used in drug discovery to understand the properties necessary to 
convert leads into good medicines [3,4].  
 
As a result of studies in the late 1990s, indicating that poor pharmacokinetics (PK) and 
toxicity were important causes of costly late-stage failures in drug development, it has 
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become widely appreciated that these areas should be considered as early as possible in the 
drug discovery process [3]. A great deal of  in vitro data on physicochemical properties and 
specific ADME processes is already available at early stages of the drug discovery process. 
These data related to new drug candidates can be used in physiologically-based 
pharmacokinetic (PBPK) models to predict, analyze and optimize the pharmacokinetics of the 
compounds [5,6]. For instance, a combination of only five compound-specific parameters 
(fraction unbound in plasma, blood plasma ratio, intrinsic clearance, pKa and octanol water 
partition coefficient) and known species-related physiological parameters are required for the 
first PK estimates of an i.v. application [5]. Along the drug discovery process, more detailed 
compound-specific data and in vivo data are generated, upon which more detailed predictions 
and analyses can be made. The PBPK model approach is flexible, in the sense that it has the 
potential to be continuously updated in the light of new information, whether physiologic, 
disease, or drug related, including up- and down-regulation of critical components [11]. In 
particular, PBPK modeling has the advantage of being able to incorporate experimental 
animal data as well as in silico-derived and in vitro data into a coherent framework, from 
which meaningful and reliable assessments can be made [10]. 
It is worth noticing that in toxicology, physiologically-based models have a longer history and 
have been successfully applied, because of the almost exclusiver reliance upon animal data 
for the assessment of toxicological risk for humans [7-9]. 
 
 
IN SILICO MODELING 
 
In the engineering sciences, computational approaches form an integral part in the developing 
process—some biological disciplines like, e.g. systems biology, have rather recently 
proceeded in the same direction [12,13]. Modeling and simulation help to analyze and 
understand large complex systems, in particular when the system comprises several subunits 
interacting in a strong and time-dependent manner. This is exactly the situation present in 
pharmacokinetics, where such subunits are typically physiological processes such as transport 
by the blood circulation, binding to macro-molecules, permeation through membranes, 
metabolism by the liver enzymes, excretion by the kidney and so on. While each of the 
processes is comparable simple, the overall behaviour is not.  
 
There is no single established model underlying pharmacokinetics, and it will remain out of 
reach in the foreseeable future. This situation is completely different from, e.g., quantum 
mechanics or electrodynamics, where the Schrödinger equation or the Maxwell equations, 
respectively, are the basis and starting point for modeling and simulation attempts. Instead, 
the type of model needed will depend on the question to be resolved and, therefore, on the 
drug development stage at which the question is addressed. In silico approaches will continue 
to evolve rapidly, just as in vitro methods did during the last decade [10]. The quality and 
predictive power of new models will be judged in comparison with experimental data as well 
as in comparison with other models (as an example see, e.g., the study in [14]). A variety of 
different models for oral absorption are avaliable[15-19]. By comparing these absorption 
models for different test compounds, it would be possible to understand the “domain of 
applicability” of each model, i.e., under which conditions and for which class of compounds 
the models give the most reliable predictions. Partition coefficients are another example; there 
are different in silico methods to determine partition coefficients [20,21]. It would be 
interesting to compare, not only the different predicted partition coefficients, but also, in silico 
pharmacokinetic studies for a list of test compounds, based on these different partition 
coefficients. This would allow for a sensitivity analysis to identify the most critical partition 
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coefficient. To support this type of comparative studies, flexibility in modeling will be 
crucial. 
 
The present status of available software tools for modeling and simulation in pharmaco-
kinetics has been thoroughly summarized in [11]. The software ranges from (i) general-
purpose high-level scientific software, such as Berkeley Madonna, Matlab, MLAB and 
Octave; (ii) bio-mathematical modeling software, like ADAPT II, ModelMaker, NONMEM, 
WinNonlin; (iii) toxicokinetic software, e.g., ACSL Toxicology Toolkit, SimuSolv and (iv) 
physiologically-based custom-designed software, such as GastroPlus, Pathway Prism, PK-
Sim and Physiolab. As stated in [11], “it appears that there is an inverse relationship between 
user-friendliness and flexibility”. However, combining flexibility with user-friendliness is 
exactly the domain of a virtual lab.  
 
The modeling situation is comparable to the situation in systems biology [12,13,22,23], where 
a large variety of modeling and simulation tools are available. Software tools like COPASI, 
E-CELL, Virtual Cell, and many more, have been designed to fulfill the needs of system 
biological modeling (a comprehensive list of software in this field can be found online under 
URL http://sbml.org). These tools are modular and open and allow for implementation of 
arbitrary models. Sometimes, typical reaction schemes are pre-implemented (like  linear or 
Michaelis-Menten type kinetics), but flexibility is almost always retained. In principle, 
software tools developed in systems biology could be used in pharmacokinetics as well; 
however, they do not support the special structure/needs in pharmacokinetics. Jointly with the 
upcoming modeling efforts there has been a collective initiative of a number of research 
institutions to standardize models in order to facilitate exchange of models between different 
tools. As a result, the Systems Biology Markup Language (SBML) was created, a computer-
readable format for representing models of biochemical reaction networks [24]. SBML is 
applicable to metabolic networks, cell-signaling pathways, regulatory networks and many 
others, and might also become interesting for PK. 
 
In the light of our experience, we see the current status of modeling in pharmacokinetics 
comparable to the status of fields like, e.g., polymer chemistry at about 10-15 years ago. Since 
then, experts in these fields have experienced that even without definite a priori knowledge of 
the “true” model and its parameters, the ongoing modeling process reveals such a tremendous 
insight into the system,  that the modeling research usually pays off after a short time. At the 
same time, significant feedback between modeling progress and experimental methods could 
be observed. Sometimes new modeling ideas required better or newly-designed experiments; 
sometimes a breakthrough of analytical techniques enforced a more detailed modeling. We 
are convinced that this progress will take place in pharmacokinetics, in a similar way, in the 
near future. The development of the design principles and concepts of a virtual lab for PK has 
already shown that modeling principles from polymer chemistry, particle technology, 
catalysis and reaction engineering can be applied here in a structural way. After all, from a 
mathematical point of view, a pharmacokinetic model is not so different to a network of 
multiple-phase bio-reactors.  
 
 
THE VISION AND THE BENEFIT 
 
It is the emerging consensus that in silico predictions are no less predictive of what occurs in 
vivo than are in vitro tests, with the decisive advantage that much less investment in 
technology, resources and time is needed [10,25]. We believe that the combination of in vitro 
experiments and in silico modeling will dramatically increase the insight and knowledge 
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about the relevant physiological and pharmacological processes in drug discovery. In the 
future, rather than performing separate target validation, biomarker identification, lead 
generation and optimization, candidate selection and preclinical development studies, these 
separate steps will be vertically integrated, accompanied by an in silico modeling process 
bringing together the knowledge gained from each of these steps into a disease-specific whole 
body model. The physiologically-based modeling approach offers a scientifically-defensible 
method (instead of just an educated guess) for the integration of these various pieces of 
information from in vitro studies and other preclinical information, in order to evaluate the 
outcome under various assumptions [26]. Each pharmaceutical company can build their own 
model  tailored to their individual indications, knowledge and experience. Rather than 
modeling, analyzing and measuring plasma or tissue drug concentrations, these disease-
specific whole body models allow the study of effect-specific processes. The modeling 
process will benefit greatly from the systems biology community and their experience, insight 
and available models on metabolic pathways, gene-regulatory networks and signaling 
pathways [12,22-24,27]. As stated in [13], the most feasible application of systems biology 
research is to create a detailed model of cell regulation, focused on particular signal-
transduction cascades and molecules to provide system-level insights into mechanism-based 
drug discovery (e.g., [28]). Such models may help to identify feedback mechanisms that offset 
the effects of drugs and predict systemic side effects. Many of the necessary foundations have 
nearly been laid; however, there is no flexible, application specific and user-friendly software 
tool available that really supports this process in an open way.  
 
 
THE VIRTUAL LAB APROACH 
 
In mathematical terms, a PBPK model consists of a set of differential equations describing the 
ADME processes of one or more compounds in a system of more than a dozen organs, each 
being possibly further subdivided into a number of phases (e.g., erythrocytes, plasma, 
interstitial and cellular space). Coding such a system in a programming language is possible, 
however cumbersome and error prone, and a subsequent extension or change of the model 
will even be more complicated. For the design of a virtual lab, it is obvious that on the one 
hand, the software tools should allow for the input of models in a very open way, yet on the 
other hand, should not force the user to enter the whole set of differential equations. Thus, an 
implementation of a static model is prohibitive, since it contradicts the requirement on 
openness of the software tool; furthermore, a purely equation-based approach is in contrast 
with the requirement of user-friendliness. However, unfortunately these are two typical 
approaches often met in engineering software packages. Instead, the requirements on 
openness and user-friendliness have to be fulfilled by the use of a sophisticated modular 
structure implemented by means of modern software concepts (cf. e.g [29]).  
 
The virtual lab should allow the implementation of a hierarchy of models suitable for the 
integration of  as much knowledge (data) as available into the model, i.e., few in vitro data at 
the beginning, followed by more detailed in vitro data and in vivo data later on. At any point, 
the model should be completely transparent; there should be neither hidden calculations nor 
parameters. From our experience, this is an important point since transparency is a 
prerequisite for confidence in the modeling process. In addition, as stated in [10], “Software 
producers need to improve transparency and state clearly the assumptions underlying their 
predictive approach”. Moreover, the integration of system biological data (e.g. from the target 
finding and validation process) should be possible, proceeding towards the simulation of 
biomarkers and effect-related processes. Of course, the use of state-of-the-art numerical 
algorithms and the possibility to easily and flexible analyze the simulation output and the 
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comparison of different models on the basis of their simulation results is self-evident. This is 
important for the a posteriori evaluation of early/coarse models in comparison with 
late/refined models, as well as for the design of new models, e.g., for oral absorption. A 
modular structure should facilitate modeling of drug-drug-interactions and support the 
development of disease specific models for the design of virtual “patients” (humans as well as 
animals) that can be exploited in the drug discovery process. 
 
Simulation scenarios
- full body model
- individual
- compounds
- dosing strategies
Simulation results
Parameter definitions
Compounds (c):
- definitions
- parameters (o)
Mixed parameters (c+i)
Individuals (i):
- definitions
- parameters (o)
Model definitions
Organs (o) + Phases
Topology templates
Physiological process library
- type (binding, metabolisms, 
etc.)
- description, formulas
- general parameter 
dependencies (o,c,i)
Full body model:
- topology
- selected processes
 
 
Figure 1: Modular structure of MEDICI-PK: All definitions, models and parameters can be entered and changed 
by the user and are not limited. Based on the defined framework (topology, model library, list of 
substances and individuals) the components of a model form a so-called “Simulation object” describing 
one simulation scenario. A project may consist of an open list of all shown structures; simulation results 
from totally different models can easily be compared. 
 
 
 
MEDICI-PK 
 
The above derived design principles and concepts have been realized for the first time in the 
virtual lab MEDICI-PK (see Table 1), demonstrating its feasibility and illustrating the 
advantages and benefits of the concept. The underlying structure can be seen in Fig. 1. A 
crucial point is the so-called orthogonality of the model and the parameters. The compounds 
and the individuals (representing either a typical, healthy species or a disease type) are 
basically a collection of parameters and the source of input for the models. The models, 
however, are established independently from the compound and the individual. They are 
based on typical physiological processes, like protein binding, diffusion across the membrane, 
metabolism and so on. Each of these typical processes can be represented by a set of 
(differential) equations, without setting up the whole body model. This guarantees that the 
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underlying physiological processes are accessible, extendable and fully transparent. When 
performing a case study, one simply has to choose the underlying whole body 
physiologically-based model, the individual (and therefore the species) and the compound 
(Fig. 2). This way, greatest flexibility is retained. For instance, simulating the same compound 
with the same model for a different species requires just two “clicks” (assuming, of course, 
that the necessary model parameters are available). To give another example: assume we want 
to simulate a pro-drug, its metabolite (the drug) and a potential interaction of the drug with 
another compound in the kidney (thinking of oseltamivir, oseltamivir phosphate (Tamiflu) 
and probenecid [30,31]). Then, in a first step one needs to choose a model, an individual and 
one of the compounds at a time to simulate their pharmacokinetics. Now, in a second step, the 
interaction needs to be included into the model. This is realized by defining two new basic 
physiological models: (i) metabolism in the liver, taking explicitly the production of the 
metabolite into account, (ii) competitive excretion in the kidney (to build this model, one can 
use the insight from competitive metabolism). Choosing these two basic physiological models 
in the whole body physiologically-based pharmacokinetic model, the overall interaction of the 
three compounds can now be studied by simulation. This nicely illustrates who easily 
interactions of different compound can be integrated into the model.  
 
                      
 
Figure 2: A Medici-PK simulation object summarizing all settings and parameters of a single simulation 
scenario. All details are assessable and can be changed in the model tree. 
 
A number of different models and simulation studies have already been realized in MEDICI-
PK in this way, e.g. a model on Cyclosporine A [32], a detailed model on the PK of 
tolbutamide and a generic PBPK model for early drug development (following [5,33]). 
Immediately extensions of the existing models have been studied (Fig. 3), e.g. incorporation 
of metabolites, comparison of different binding and tissue distribution models, drug-drug-
interaction studies, comparison between different species (human, rat, and so on).  
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Figure 3: Typical simulation output of a MEDICI-PK case study. The results for all organs and phases can be 
visualized and compared. The graphic shows concentration time curves, where the blue line correspond to the 
results obtained by use of a more refined model in comparison to the result of a coarser model (red line). 
 
 
CONCLUSION 
 
This article presents the design principles and concepts of a virtual lab approach - 
implemented in the program package Medici-PK – that supports in silico modeling and 
simulation in PK/PD. The concept is especially tailored to serve the needs in drug discovery. 
Based on our experience in other fields of chemistry and biology we see a high potential for in 
silico PK/PD approaches in the drug discovery and development process if properly realized. 
When starting the modeling and simulation activities, there will soon be a first benefit: 
modeling eventually brings together people with different backgrounds and different company 
internal affiliations–thereby increasing the flux of information across different process stages 
(in this case ideally between the research, development and clinical phase). Moreover, in the 
process of developing an appropriate model, important modeling questions have to be 
addressed. What are the most relevant physiological processes and mechanisms? Is there any 
detailed knowledge about these processes or are they (partially) unknown? Are there 
competing hypotheses about important mechanisms? A further benefit is the integration of in 
silico, in vitro or in vivo data into a coherent framework by which they both (model and data) 
undergo a kind of consistency check. Once a first model has been established, hypotheses can 
be generated and tested by simulation. Having gained first confidence in the model, 
predictions generated by simulation studies will influence the design of future experimental 
studies (in vitro and in vivo). As can be seen in many different fields this feedback loop is 
often the beginning of a substantial change in the quality of models and understanding of the 
processes of interest.  
 
It is important to note that building a comprehensive and predictive model usually cannot be 
realized in a few days. The decision to do modeling at best implies a long-term directive. It is 
a process gaining and accumulating new insights from the very beginning, but the “final” 
model will hardly look like the first attempts or approaches published elsewhere. For PK-
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modeling this means that a compound should be continuously monitored in silico along its 
way through the research, development and clinical phases. Once established, a good model 
can be ‘re-used’ for every new drug candidate thereby decreasing the amount of work to be 
invested per compound and ensuring an information flux back from the (data rich) clinical 
phase to the target finding/validation and lead generation phase.  
 
 
Table 1: Important feature of the virtual lab MEDICI-PK (for more details, see text) 
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